DETERMINATION OF PRODUCT PROFIT. Within [ * ] after the end of each calendar quarter following the First Commercial Sale of a Co-Funded Product, PDL shall provide EXEL with a statement detailing (i) PDL's Net Sales and the Product Profit incurred or received, as applicable, in the previous calendar quarter with respect to each Co-Funded Product, (ii) the cumulative Product Profit for all Co-Funded Products and (iii) the PDL Share and the EXEL Share for that quarter (the "Quarterly Report"). Such statement shall be accompanied by appropriate supporting information.
Appears in 4 contracts
Samples: Collaboration Agreement (Protein Design Labs Inc/De), Collaboration Agreement (Protein Design Labs Inc/De), Collaboration Agreement (Exelixis Inc)
